Synthesis and Antioxidative Potency of Novel Amidino Substituted Benzimidazole and Benzothiazole Derivatives by Livio Racané et al.




  O R I G I N A L  S C I E N T I F I C  P A P E R    
  
 Croat. Chem. Acta 2017, 90(2), 187–195  
 Published online: July 20, 2017 




Synthesis and Antioxidative Potency of Novel 
Amidino Substituted Benzimidazole and 
Benzothiazole Derivatives 
 
Livio Racané,1 Maja Cindrić,2 Nataša Perin,2 Petra Roškarić,2 Kristina Starčević,3,* Tomislav Mašek,4 Maja Maurić,3 
Jasna Dogan,5 Grace Karminski-Zamola2,# 
 
 
1 Department of Applied Chemistry, Faculty of Textile Technology, University of Zagreb, Prilaz baruna Filipovića 28a, 10000 Zagreb, Croatia 
2 Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev trg 19, 10000 Zagreb, Croatia 
3 Department of Animal Husbandry, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, HR-10000 Zagreb, Croatia 
4 Department of Animal Nutrition and Dietetics, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia 
5 Pliva – TAPI R&D Chemistry, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia 
* Corresponding author’s e-mail address: kstarcevic@vef.hr 
# Corresponding author’s e-mail address: gzamola@fkit.hr 
 
RECEIVED: May 09, 2017    REVISED: June 17, 2017    ACCEPTED: June 20, 2017 
   THIS PAPER IS DEDICATED TO PROF. MIRJANA METIKOŠ-HUKOVIĆ ON THE OCCASION OF HER BIRTHDAY   
 
Abstract: Herein we present the synthesis of versatile amidino substituted benzothiazole 3–10 and benzimidazole 12–19 derivatives substituted 
with the variable number of hydroxy and methoxy groups. Furthermore, the synthesized compounds were explored for their antioxidative 
activity in vitro by using three biological assays, namely DPPH, ABTS and FRAP. The obtained results indicated that the variable number of 
hydroxy groups together with the type of the amidino substituent strongly influenced the antioxidative activity and reducing power of tested 
compounds. The most promising antioxidative activity showed trihydroxy substituted compounds 6, 10, 15 and 19. In general, it was noticed 
that unsubstituted amidino group induced the more pronounced activity in comparison to derivatives bearing 2-imidazolinyl group. 
 





ENZIMIDAZOLES and benzothiazoles, amongst all 
nitrogen heterocycles, are one of the most important 
building motifs of many essential and physiologically active 
natural, semisynthetic or synthetic pharmaceuticals.[1] 
Being fundamental structural parts of a number of 
biologically active derivatives, there has been an increasing 
interest in medicinal chemistry in the role of both 
heterocycles due to their possible pharmacological, 
chemical or industrial applications.[2,3] Their derivatives 
display a broad spectrum of different biological features 
such as anticancer, antiviral, antibacterial, antifungal, anti-
inflammatory etc.[4–6] 
 In our research group we have published several 
publications regarding antiproliferative and antitumor 
activity of versatile benzimidazole and benzothiazole 
derivatives bearing different amidino supstituents.[7,8] 
Among all amidino substituted benzazole derivatives, the 
ones with the cyclic amidino substituent, namely 2-
imidazolinyl group, showed the most significant anti-
proliferative activity in vitro with IC50 values in sub-
micromolar range of concentrations.[9] Almost all 
previously synthesized active derivatives have been 
designed to have cationic amidino substituents which have 
significantly improve their biological activity. Amidine 
substituents placed at the termini of the molecule have 
great importance in the molecule - biological target 
interactions allowing the formation of the stable complex 
with biologically important molecules. Also, 2-imidazolinyl 
substituted tetracyclic benzimidazole derivatives showed 
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strong DNA intercalators and inhibited human topo-
isomerase II.[10] On the other hand, acyclic benzimidazoles 
and benzothiazoles have been proven to be a selective DNA 
minor groove binders which was confirmed with several 
spectroscopic methods. Regarding the 2-phenylbenzo-
thiazole derivatives, we have shown that their antiprolife-
rative activity strongly depends on the type of amidino 
group as well as on their position on the targeted 
molecule.[7,9] Nowadays, the attention of medicinal 
chemists is focused also on the development of the novel 
antioxidative agents, especially after it has been evidenced 
that oxidative damage of important biomacromolecules is 
directly connected with the pathogenesis of various 
diseases.[11,12] Thus, the reactive oxygen species (ROS) 
through the damage of cellular biomacromolecules like 
proteins, lipids or DNA/RNA may be playing an important 
role in the development of cancer, atherosclerosis, aging or 
rheumatoid arthritis.[13,14] One of the chain reactions 
caused by ROS is lipid peroxidation which could generate 
mutagenic products with carcinogenic properties.[15] Many 
natural and synthetic products possess antioxidative 
capacity and are studied as a promising antioxidants which 
could reduce the rate of ROS production and the oxidation 
of biomacromolecules.[16] Several publications described 
the antioxidative activity and potential of benzimidazole 
and benzothiazole derivatives as antioxidative agents. B. 
Zhou and co-authors have been published the antioxidative 
activity of a series of 2-aryl benzimidazole derivatives 
(Figure 1).[17] Obtained results revealed that derivative 
bearing a hydroxy group at the 5-position of benzimidazole 
nuclei posses a comparable or better antioxidant activity in 
comparison to standard antioxidant tert-butylhydroqui-
none (TBHQ). On the other hand a series of 2-aryl substitu-
ted benzothiazoles (Figure 1) has also show antioxidative 
activity and significant radical scavenging potential due to 
the presence of electron donating substituent.[18] 
 All the above mentioned facts guided us to design 
and synthesize novel amidino substituted benzazole deriva-
tives in order to evaluate their antioxidant potential. The 
obtained results are discussed in terms of SAR to define the 
influence of the type of amidino group and heterocyclic 
nuclei as well as the number of hydroxy groups attached on 






Melting points were determined by means of Original 
Kofler Mikroheitztisch apparatus (Reichert, Wien). The 1H 
NMR and the 13C NMR spectra were recorded with the 
Bruker Avance DPX-300 or Bruker AV-600 using TMS as 
internal standard. Chemical shifts are reported in parts per 
million (ppm) relative to TMS. LC-MS was performed on the 
Agilent 6120 Quadrupole coupled to the Agilent 1290 
Infinity II UHPLC using electrospray ionization (ESI). 
 
SYNTHESIS 
Synthesis of 2-amino-5-amidiniumbenzenethiolate 2a and 
2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzene-
thiolate hydrate 2b were carried out according to the 
literature.[19] Synthesis of 4-amidinium-1,2-phenylenedi-
amine 11a and 2-(3,4-diaminophenyl)-4,5-dihydro-1H-
imidazol-3-ium chloride 11b were carried out according to 
the literature.[20] 
 
General method for the synthesis of benzothiazole 
derivatives 3–10 
A mixture of the corresponding aldehyde 1a–1d (0.5 mmol) 
and 2-amino-5-amidiniumbenzenethiolate 2a (0.5 mmol) or 
2-amino-5-(4,5-dihydro-1H-imidazol-3-ium-2-yl)benzenethi-
olate hydrate 2b (0.5 mmol) in glacial acetic acid (5 mL) was 
stirred at reflux under nitrogen for 3 h, followed by the 
addition of concentrated hydrochloric acid (0.5 mL) and addi-
tionally stirred at room temperature for 1 h. After cooling 
overnight, the crude product was filtered off, washed with 
acetone and crystallized to obtain pure compounds 3–10. 
 
6-Amidinium-2-(2-hydroxyphenyl)benzothiazole chloride 3 
Using above described method from 2-hydroxybenzal-
dehyde 1a (0.061 g, 0.5 mmol), 2-amino-5-amidiniumben-
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zenethiolate 2a (0.084 g, 0.5 mmol) and crystallization from 
0.1 M hydrochloric acid/acetone mixture was obtained 
0.089 g (58.2 %) of colourless solid, m.p. 292–296 °C; 1H 
NMR (300 MHz, DMSO-d6) δ/ppm: 11.70 (bs, 1H, -OH), 9.50 
(s, 2H, -C(NH2)2+), 9.28 (s, 2H, -C(NH2)2+), 8.69 (d, 1H, J = 1.6 
Hz, Ar-H), 8.34 (dd, 1H, J = 8.0 Hz, J = 1.6 Hz, Ar-H), 8.23 (d, 
1H, J = 8.6 Hz, Ar-H), 7.93 (dd, 1H, J = 8.6 Hz, J = 1.9 Hz, Ar-
H), 7.46 (m, 1H, Ar-H), 7.20 (d, 1H, J = 7.7 Hz, Ar-H), 7.05 (m, 
1H, Ar-H); 13C NMR (75 MHz, DMSO-d6) δ/ppm: 167.9, 
165.6, 156.7, 154.7, 135.2, 133.1, 128.6, 125.9, 123.9, 





Using above described method from 2,4-dihydroxyben-
zaldehyde 1b (0.069 g, 0.5 mmol), 2-amino-5-amidinium-
benzenethiolate 2a (0.084 g, 0.5 mmol) and crystallization 
from 0.1 M hydrochloric acid was obtained 0.083 g (51.8 %) 
of beige solid, m.p. > 300 °C; 1H NMR (300 MHz, DMSO-d6) 
δ/ppm: 11.57 (s, 1H, -OH), 10.34 (s, 1H, -OH), 9.42 (s, 2H, -
C(NH2)2+), 9.14 (s, 2H, -C(NH2)2+), 8.59 (s, 1H, Ar-H), 8.14–
8.10 (m, 2H, Ar-H), 7.88 (d, 1H, J = 8.6 Hz, Ar-H), 6.57 (s, 1H, 
Ar-H), 6.49 (d, 1H, J = 8.7 Hz, Ar-H); 13C NMR (75 MHz, 
DMSO-d6) δ/ppm: 168.9, 165.5, 162.3, 158.5, 154.9, 134.3, 
130.1, 125.7, 123.1, 122.5, 121.2, 110.4, 108.6, 102.6; LC-
MS (ESI) m/z: 286.1 [(M-Cl–)+]. 
 
6-Amidinium-2-(2-hydroxy-4-methoxyphenyl)benzothia-
zole chloride 5 
Using above described method from 2-hydroxy-4-
methoxybenzaldehide 1c (0.076 g, 0.5 mmol), 2-amino-5-
amidiniumbenzenethiolate 2a (0.084 g, 0.5 mmol) and 
crystallization from 0.1 M hydrochloric acid was obtained 
0.098 g (58.3 %) of colourless solid, m.p. = 289–293 °C; 1H 
NMR (300 MHz, DMSO-d6) δ/ppm: 11.84 (bs, 1H, -OH), 9.45 
(s, 2H, -C(NH2)2+), 9.17 (s, 2H, -C(NH2)2+), 8.62 (d, 1H, J = 1.6 
Hz, Ar-H), 8.22 (d, 1H, J = 8.8 Hz, Ar-H), 8.16 (d, 1H, J = 8.6 
Hz, Ar-H), 7.90 (dd, 1H, J = 8.6 Hz, J = 1.9 Hz, Ar-H), 6.70 (d, 
1H, J = 2.3 Hz, Ar-H), 6.66 (dd, 1H, J = 8.9 Hz, J = 2.4 Hz, Ar-
H), 3.83 (s, 3H, -OCH3); 13C NMR (75 MHz, DMSO-d6) δ/ppm: 
168.3, 165.5, 163.3, 158.5, 154.9, 134.6, 130.0, 125.9, 
123.4, 122.7, 121.6, 111.9, 107.2, 101.1, 55.4; LC-MS (ESI) 




Using above described method from 2,3,4-trihydroxyben-
zaldehyde 1d (0.077 g, 0.5 mmol), 2-amino-5-amidinium-
benzenethiolate 2a (0.084 g, 0.5 mmol) and crystallization 
from 0.1 M hydrochloric acid was obtained 0.062 g (36.7 %) 
of colourless solid, m.p. > 300 °C; 1H NMR (300 MHz, DMSO-
d6) δ/ppm: 10.92 (bs, 1H, -OH), 10.07 (bs, 1H, -OH), 9.46 (s, 
2H, -C(NH2)2+), 9.23 (s, 2H, -C(NH2)2+), 8.95 (bs, 1H, -OH), 
8.62 (s, 1H, Ar-H), 8.14 (d, 1H, J = 8.5 Hz, Ar-H), 7.90 (d, 1H, 
J = 8.5 Hz, Ar-H), 7.61 (d, 1H, J = 8.8 Hz, Ar-H), 6.57 (d, 1H, J 
= 8.8 Hz, Ar-H); 13C NMR (151 MHz, DMSO-d6) δ/ppm: 
169.8, 165.5, 154.9, 150.1, 147.2, 134.1, 133.0, 125.9, 




benzothiazole chloride 7 
Using above described method from 2-hydroxyben-
zaldehyde 1a (0.061 g, 0.5 mmol), 2-amino-5-(4,5-dihydro-
1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 2b (0.5 
mmol) and crystallization from 0.1 M hydrochloric acid was 
obtained 0.103 g (62.1 %) of colourless solid, m.p. 299–304 
°C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 11.72 (s, 1H, -OH), 
10.86 (s, 2H, -C(NH-)2+), 8.90 (s, 1H, Ar-H), 8.34 (d, 1H, J = 
6.9 Hz, Ar-H), 8.25 (d, 1H, J = 8.6 Hz, Ar-H), 8.13 (d, 1H, J = 
8.5 Hz, Ar-H), 7.47 (m, 1H, Ar-H), 7.21 (d, 1H, J = 8.2 Hz, Ar-
H), 7.05 (m, 1H, Ar-H), 4.04 (s, 4H, -CH2CH2-); 13C NMR (75 
MHz, DMSO-d6) δ/ppm: 168.3, 164.6, 156.8, 155.0, 135.5, 
133.2, 128.6, 126.3, 123.5, 122.5, 119.7, 118.6, 118.0, 
117.0, 44.4; LC-MS (ESI) m/z: 296.1 [(M-Cl-)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2,4-dihydroxy 
phenyl)benzothiazole chloride 8 
Using above described method from 2,4-dihydroxy-
benzaldehyde 1b (0.069 g, 0.5 mmol), 2-amino-5-(4,5-
dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 
2b (0.5 mmol) and crystallization from 0.1 M hydrochloric 
acid was obtained 0.101 g (58.4 %) of beige solid, m.p. > 300 
°C; 1H NMR (600 MHz, DMSO-d6) δ/ppm: 11.58 (s, 1H, -OH), 
10.69 (s, 2H, -C(NH-)2+), 10.36 (s, 1H, -OH), 8.76 (d, 1H, J = 
1.7 Hz, Ar-H), 8.16-8.13 (m, 2H, Ar-H), 8.04 (dd, 1H, J = 8.6 
Hz, J = 1.9 Hz, Ar-H), 6.58 (d, 1H, J = 2.3 Hz, Ar-H), 6.49 (dd, 
1H, J = 8.8 Hz, J = 2.3 Hz, Ar-H), 4.04 (s, 4H, -CH2CH2-); 13C 
NMR (151 MHz, DMSO-d6) δ/ppm: 169.0, 164.6, 162.4, 
158.6, 155.3, 134.7, 130.2, 126.1, 123.1, 121.6, 117.1, 
110.6, 108.7, 102.6, 44.3; LC-MS (ESI) m/z: 312.1 [(M-Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2-hydroxy-4-
methoxyphenyl) benzothiazole chloride 9 
Using above described method from 2-hydroxy-4-
methoxybenzaldehide 1c (0.076 g, 0.5 mmol), 2-amino-5-
(4,5 - dihydro - 1H - imidazol - 3 - ium - 2 - yl)benzenethiolate 
hydrate 2b (0.5 mmol) and crystallization from 0.1 M 
hydrochloric acid/acetone mixture was obtained 0.089 g 
(52.6 %) of pale yellow solid m.p. 291–296 °C; 1H NMR (300 
MHz, DMSO-d6) δ/ppm: 10.99 (bs, 3H, -OH + -C(NH-)2+), 
8.81 (s, 1H, Ar-H), 8.24 (d, 1H, J = 8.9 Hz, Ar-H), 8.18 (d, 1H, 
J = 8.6 Hz, Ar-H), 8.08 (d, 1H, J = 8.6 Hz, Ar-H), 6.71 (s, 1H, 
Ar-H), 6.66 (d, 1H, J = 8.9 Hz, Ar-H), 4.04 (s, 4H, -CH2CH2-), 
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168.7, 164.6, 163.4, 158.5, 155.1, 134.7, 123.0, 126.1, 
123.1, 121.8, 117.4, 111.8, 107.1, 101.1, 55.3, 44.3; LC-MS 
(ESI) m/z: 326.1 [(M-Cl–)+]. 
 
6-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2,3,4-
trihydroxyphenyl)benzothiazole chloride 10 
Using above described method from 2,3,4-trihydroxy-
benzaldehyde 1d (0.077 g, 0.5 mmol), 2-amino-5-(4,5-
dihydro-1H-imidazol-3-ium-2-yl)benzenethiolate hydrate 
2b (0.5 mmol) and crystallization from 0.1 M hydrochloric 
acid was obtained 0.083 g (45.6 %) of beige solid, m.p. > 300 
°C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 10.89 (bs, 1H, -
OH), 10.70 (bs, 2H, -C(NH-)2+), 10.11 (bs, 1H, -OH), 8.92 (bs, 
1H, -OH), 8.76 (d, 1H, J = 1.4 Hz, Ar-H), 8.16 (d, 1H, J = 8.6 
Hz, Ar-H), 8.04 (dd, 1H, J = 8.6 Hz, J = 1.7 Hz, Ar-H), 7.63 (d, 
1H, J = 8.8 Hz, Ar-H), 6.57 (d, 1H, J = 8.8 Hz, Ar-H), 4.04 (s, 
4H, -CH2CH2-); 13C NMR (75 MHz, DMSO-d6) δ/ppm: 170.0, 
164.6, 155.2, 150.2, 147.3, 134.4, 133.0, 126.2, 123.1, 
121.6, 119.5, 117.3, 111.3, 108.7, 44.3; LC-MS (ESI) m/z: 
328.1 [(M-Cl–)+]. 
 
General method for the synthesis of benzimidazole 
derivatives 12–19 
A mixture of equimolar amounts of corresponding 
aldehyde 1a-1d and 4-amidinium-1,2-phenylenediamine 
11a or 2-(3,4-diaminophenyl)-4,5-dihydro-1H-imidazol-3-
ium chloride 11b in absolute ethanol with p-benzoquinone 
was stirred at reflux for 4 hours. The crude product was 
then filtered off, washed with diethyl ether and crystallized 




Using above described method from 2-hydroxybenz-
aldehyde 1a (0.100 g, 0.8 mmol), 4-amidinium-1,2-
phenylenediamine 11a (0.153 g, 0.8 mmol) and p-
benzoquinone (0.089 g, 0.8 mmol) in absolute ethanol (3 
mL) was obtained 0.043 g (18.2 %) of colourless solid; m.p. 
> 300 °C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 13.62 (bs, 
1H, -OH), 12.83 (bs, 1H, Bim-NH), 9.36 (s, 2H, -C(NH2)2+), 
9.02 (s, 2H, -C(NH2)2+), 8.23–8.20 (m, 2H, Ar-H), 7.87 (d, 1H, 
J =8.5 Hz, Ar-H), 7.74 (dd, 1H, J = 8.5 Hz, J = 1.5 Hz, Ar-H), 
7.48–7.43 (m, 1H, Ar-H), 7.12–7.04 (m, 2H, Ar-H); 13C NMR 
(75 MHz, DMSO-d6) δ/ppm: 166.4, 158.4, 133.4, 128.1, 





Using above described method from 2,4-dihydroxyben-
zaldehyde 1b (0.100g, 0.7 mmol), 4-amidinium-1,2-
phenylenediamine 11a (0.135 g, 0.7 mmol) and p-
benzoquinone (0.078 g, 0.7 mmol) in absolute ethanol (3.5 
mL) was obtained 0.023 g (10.4 %) of violet solid; m.p. > 300 
°C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 13.46 (bs, 1H, -
OH), 12.73 (bs, 1H, Bim-NH), 10.16 (bs, 1H, -OH), 9.30 (bs, 
2H, -C(NH2)2+), 8.99 (bs, 2H, -C(NH2)2+), 8.12 (bs, 1H, Ar-H), 
7.99 (d, 1H, J = 8.5 Hz, Ar-H), 7.77 (d, 1H, J = 7.7 Hz, Ar-H), 
7.68 (d, 1H, J = 8.6 Hz, Ar-H), 6.49 (dd, 1H, J = 8.5 Hz, J = 2.2 
Hz, Ar-H), 6.45 (d, 1H, J = 2.1 Hz, Ar-H); 13C NMR (75 MHz, 
DMSO-d6) δ/ppm: 166.0, 165.9, 161.7, 161.5, 160.1, 159.9, 
155.5, 154.8, 145.0, 140.8, 137.2, 133.0, 128.6, 128.4, 
122.3, 122.0, 121.4, 121.3, 117.8, 117.5, 111.7, 111.6, 108.0 




methoxyphenyl)benzimidazole chloride 14 
Using above described method from 2-hydroxy-4-
methoxybenzaldehide 1c (0.057 g, 0.4 mmol), 4-
amidinium-1,2-phenylenediamine 11a (0.070 g, 0.4 mmol) 
and p-benzoquinone (0.041 g, 0.4 mmol) in absolute 
ethanol (5 mL) was obtained 0.058 g (48.5 %) of dark grey 
solid; m.p. > 300 °C; 1H NMR (600 MHz, DMSO-d6) δ/ppm: 
13.93 (s, 1H, -OH), 13.87 (s, 1H, -OH), 13.01 (s, 1H, Bim-NH), 
12.93 (s, 1H, Bim-NH), 9.44 (s, 2H, -C(NH2)2+), 9.37 (s, 2H, -
C(NH2)2+), 9.15 (s, 4H, -C(NH2)2+), 8.25 –8.07 (m, 4H, Ar-H), 
7.88 – 7.67 (m, 4H, Ar-H), 6.66 (dd, 2H, J = 8.8, J =2.4 Hz, Ar-
H), 6.64 (d, 2H, J = 2.3 Hz, Ar-H), 3.82 (s, 6H, -OCH3); 13C 
NMR (75 MHz, DMSO-d6) δ/ppm: 166.5, 163.3, 160.5, 
128.8, 122.9, 107.4 (2C), 105.8, 102.0 (2C), 55.9; LC-MS (ESI) 




Using above described method from 2,3,4-trihydroxyben-
zaldehyde 1d (0.100 g, 0.7 mmol), 4-amidinium-1,2-
phenylenediamine 11a (0.121 g, 0.7 mmol) and p-
benzoquinone (0.070 g, 0.7 mmol) in absolute ethanol (3 
mL) was obtained 0.017 g (8.2 %) of light brown solid; m.p. 
> 300 °C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 13.51 (bs, 
1H, -OH), 12.88 (bs, 1H, Bim-NH), 9.66 (bs, 1H, -OH), 9.33 
(s, 2H, -C(NH2)2+), 8.99 (s, 2H, -C(NH2)2+), 8.58 (bs, 1H, -OH), 
8.14 (bs, 1H, Ar-H), 7.81–7.78 (m, 1H, Ar-H), 7.72–7.69 (m, 
1H, Ar-H), 7.51 (d, 1H, J = 8.6 Hz, Ar-H), 6.53 (d, 1H, J = 8.7 
Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δ/ppm: 166.4, 
149.9, 148.9, 133.7, 122.9, 122.0, 118.0, 108.4 (2C), 104.7; 
LC-MS (ESI) m/z: 285.3 [(M-Cl–)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2-
hydroxyphenyl)benzimidazole chloride 16 
Using above described method from 2-hydroxyben-
zaldehyde 1a (0.100 g, 0.9 mmol), 2-(3,4-diaminophenyl)-
4,5-dihydro-1H-imidazol-3-ium chloride 11b (0.17 4g, 0.9 
mmol) and p-benzoquinone (0.089 g, 0.9 mmol) in absolute 
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solid; m.p. > 300 °C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 
13.96 (bs, 1H, -OH), 12.62 (bs, 1H, Bim-NH), 10.70 (s, 2H, -
C(NH-)2+), 8.42 (s, 1H, Ar-H), 8.26 (d, 1H, J = 7.3 Hz, Ar-H), 
7.92 (d, 1H, J = 8.6 Hz, Ar-H), 7.87 (d, 1H, J = 8.5 Hz, Ar-H), 
7.47–7.41 (m, 1H, Ar-H), 7.11–7.02 (m, 2H, Ar-H), 4.03 (s, 
4H, -CH2CH2-); 13C NMR (150 MHz, DMSO-d6) δ/ppm: 165.2, 
158.0, 157.8, 146.6, 132.6, 127.5, 119.4 (2C), 117.2 (2C), 




dihydroxyphenyl)benzimidazole chloride 17 
Using above described method from 2,4-dihydroxy-
benzaldehyde 1b (0.080 g, 0.6 mmol), 2-(3,4-diami-
nophenyl)-4,5-dihydro-1H-imidazol-3-ium chloride 11b 
(0.123 g, 0.6 mmol) and p-benzoquinone (0.063 g, 0.6 
mmol) in absolute ethanol (3.5 mL) was obtained 0.035 g 
(18.2 %) of grey-violet solid; m.p. > 300 °C; 1H NMR (600 
MHz, DMSO-d6) δ/ppm: 13.70 (bs, 1H, -OH), 13.58 (bs, 1H, 
-OH), 12.75 (s, 1H, Bim-NH), 12.58 (s, 1H, Bim-NH), 10.56 
(bs, 4H, -C(NH-)2+), 10.23 (s, 1H, -OH), 10.21 (s, 1H, -OH), 
8.35 (s, 1H, Ar-H), 8.24 (s, 1H, Ar-H), 8.06 (d, 1H, J = 8.3 Hz, 
Ar-H), 7.99 (d, 1H, J = 7.1 Hz, Ar-H), 7.85–7.82 (m, 3H, Ar-
H), 7.77 (d, 1H, J = 7.2 Hz, Ar-H), 6.49 (d, 2H, J = 8.6 Hz, Ar-
H), 6.45 (s, 2H, Ar-H), 4.02 (s, 8H, -CH2CH2-); 13C NMR (75 
MHz, DMSO-d6) δ/ppm: 165.8, 162.2, 160.4, 129.1, 123.1, 
115.9, 108.5 (2C), 104.5, 103.5 (2C), 44.7 (2C); LC-MS (ESI) 
m/z: 298.2 [(M-Cl–)+]. 
 
5(6)-(4,5-Dihydro-1H-imidazol-3-ium-2-yl)-2-(2-hydroxy-4-
methoxyphenyl)benzimidazole chloride 18 
Using above described method from 2-hydroxy-4-
methoxybenzaldehide 1c (0.071 g, 0.5 mmol), 2-(3,4-
diaminophenyl)-4,5-dihydro-1H-imidazol-3-ium chloride 
11b (0.100 g, 0.5 mmol) and p-benzoquinone (0.051 g, 0.5 
mmol) in absolute ethanol (5 mL) was obtained 0.103 g 
(63.6 %) of dark grey solid; m.p. > 300 °C; 1H NMR (600 MHz, 
DMSO-d6) δ/ppm: 13.89 (bs, 1H, -OH), 12.82 (bs, 1H, Bim-
NH), 10.72 (bs, 2H, -C(NH-)2+), 8.37 (bs, 1H, Ar-H), 8.18 (bs, 
1H, Ar-H), 7.89 (s, 1H, Ar-H), 7.82 (s, 1H, Ar-H), 6.66 (dd, 1H, 
J = 8.7, J = 2.3 Hz, Ar-H), 6.63 (d, 1H, J = 2.3 Hz, Ar-H), 4.02 
(s, 4H, -CH2CH2-), 3.83 (s, 3H, -OCH3); 13C NMR (75 MHz, 
DMSO-d6) δ/ppm: 165.8, 163.4, 128.9, 123.2, 116.0, 107.4 




trihydroxyphenyl)benzimidazole chloride 19 
Using above described method from 2,3,4-trihydroxyben-
zaldehyde 1d (0.100 g, 0.7 mmol), 2-(3,4-diaminophenyl)-
4,5-dihydro-1H-imidazol-3-ium chloride 11b (0.138 g, 0.7 
mmol) and p-benzoquinone (0.070 g, 0.7 mmol) in absolute 
ethanol (3 mL) was obtained 0.050 g (22.2 %) of brown 
solid; m.p. > 300 °C; 1H NMR (300 MHz, DMSO-d6) δ/ppm: 
13.51 (bs, 1H, -OH), 11.19 (bs, 2H, -C(NH-)2+), 10.73 (bs, 1H, 
-OH), 10.61 (s, 1H, -OH), 9.11–9.08 (m, 1H, Ar-H), 8.54 (d, 
1H, J = 8.8 Hz, Ar-H), 8.46–8.40 (m, 1H, Ar-H), 7.94 (bs, 1H, 
Ar-H), 7.52 (d, 1H, J = 7.7 Hz, Ar-H), 4.14 (s, 4H, -CH2CH2-), 
4.05 (s, 4H, -CH2CH2-); LC-MS (ESI) m/z: 311.3 [(M-Cl–)+]. 
Antioxidative Activity 
Determination of the reducing activity of the stable radical 
1,1-diphenyl-picrylhydrazyl (DPPH) 
The determination of reducing activity of the stable DPPH 
radical was measured according to previously reported 
procedure with modification.[21] Briefly, to solution of DPPH 
(final concentration 100µM) in methanol was added equal 
volume of the tested compounds various concentrations 
dissolved in DMSO. The assay was carried out in a 96 well 
microtiter plate. Methanol and DMSO was used as control 
solution. Sample blank were also performed.  
 After 30 min in dark at room temperature the absor-
bance was recorded at 517 nm on microplate reader 
µQuant (Biotec Inc.). All measures were done in triplicate and 
averaged. The results were presented as IC50 in Table 1. 
 
Free radical scavenging ability by the use of a stable ABTS 
radical cation (2,2’-azinobis-(3-ethylbenzthiazoline-6-
sulphonic acid) 
The total antioxidant activity assay was adjusted for 
microplate reader.[22] For the standard ABTS assay, ABTS•+ 
was prepared by mixing an ABTS stock solution (7 mM in 
water) with 2.45 mM potassium persulfate and left in dark 
at room temperature for 12-16 h until reaching a stable 
oxidative state. Before analysis, the ABTS•+ solution was 
diluted 100 times with methanol to obtain an absorbance 
of 0.700 (0.01 at 734 nm). The radical was stable in this 
form for more than two days when stored in the dark at 
room temperature. Standards and solutions of tested 
compounds (20 µL) were mixed with working ABTS•+ 
radical cation solution (280 µL) to each well the microplate, 
shake and incubate at room temperature for 5 min. The 
decrease of absorbance at 734 nm was recorded by 
microplate reader µQuant (Biotec Inc.). Methanol (without 
ABTS•+ solution) was used as a control and BHT as reference 
compound. All compounds were tested in triplicate and 
averaged. Results were expressed as IC50 and presented in 
Table 1. 
 
Determination of Ferric Reducing/Antioxidant Power 
(FRAP assay) 
The FRAP method was adjusted for a 96-well microplate 
according to previously reported procedure.[23] The 
antioxidant capacity of the tested compounds was 
estimated as their power to reduce the TPTZ-Fe(III) to TPTZ-




192 L. RACANÉ et al.: Antioxidative Potency of Novel Benzazoles 
 




solution of 10 mM TPTZ and 20 mM ferric chloride was 
diluted in 300 mM sodium acetate buffer (pH 3.6) at a ratio 
of 1:1:10. The tested compound solution (20 µl) was added 
to the 96-well microplate followed by working FRAP 
solution (280 µl). The mixture was shaken and incubated 30 
min at 37 °C in the dark. Final concentration of tested 
compounds was 0.01 mM for all except for compounds 6, 
10, 15 and 19 (250 µM). The absorbance at 593 nm was 
recorder using microplate reader µQuant (Biotec Inc.). For 
the standard curve construction ferrous sulphate (FeSO4 x 
7H2O) was used and range of standard curve was 20–2000 
µmol/L. All results were then expressed as Fe2+ equivalents 
(Fe2+ µmol). All compounds were tested in triplicate and the 
results were averaged and presented in Table 1. 
 
Statistical analysis 
Calculation of IC50 value is performed by using 
GraphPadPrism software (GraphPad Software, Inc. La Jolla, 
CA USA 2012). Briefly, individual concentration effect 
curves are generated by plotting the logarithm of the 
concentration of tested compounds (X) against corres-
ponding percent inhibition values (Y) using least squares fit. 
All experiments were tested at least three times. Results 
were expressed as mean ± standard deviation (SD) and 
analyzed using the Student’s t-test to assess the statistical 
significance using the Statistica software (STATISTICA 2010 
program, Tulsa, OK, USA). P values < 0.05 were regarded as 
significant. 
 
RESULTS AND DISCUSSION 
Chemistry 
The synthesis of 6-amidino-2-arylbenzothiazole derivatives 
(3–10) was carried out by condensation reaction 
(Scheme 1). Recently, we found glacial acetic acid to be an  
efficient solvent for direct condensation of aldehydes and  
amidino substituted 2-aminothiophenoles giving rise to  
the corresponding 2-substituted-6-amidinobenzothiazolyl 
compounds in high yield without the need of any catalyst 
or oxidant.[24] Consequently, cyclocondensation of 2-
amino-5-amidiniumbenzenethiolate 2a[19] and 2-amino-5-
(4,5 - dihydro - 1H - imidazol - 3 - ium - 2 - yl)-benzenethiolate 
2b[19] with commercially available aldehydes 1a–1d in 
refluxing acetic acid followed by quenching with 
hydrochloric acid afforded targeted cationic 6-amidino-2-
arylbenzothiazole compounds which were isolated as 
hydrochloride salts. The zwitterionic precursor 2a and 2b 
were prepared by Pinner reaction from 6-
Table 1. IC50 values of 2-arylbezimidazoles and benzothiazoles for DPPH and ABTS free radical scavenging activity* 
 
Cpd R1 R2 R3 X Am 
Scavenging activity (IC50 µM) 
DPPH ABTS 
3 OH H H S unsubstituted >100 >100 
4 OH H OH S unsubstituted >100 13.34±0.8(b) 
5 OH H OCH3 S unsubstituted no >100 
6 OH OH OH S unsubstituted 23.89±4.7(a) 7.64±1.5(b) 
7 OH H H S 2-imidazolinyl no >100 
8 OH H OH S 2-imidazolinyl >100 9.83±0.9(b) 
9 OH H OCH3 S 2-imidazolinyl no >100 
10 OH OH OH S 2-imidazolinyl 34.76±7.0(b) 9.33±0.7(b) 
12 OH H H NH unsubstituted no no 
13 OH H OH NH unsubstituted >100 10.74±0.5(b) 
14 OH H OCH3 NH unsubstituted >100 53.59±11.4(b) 
15 OH OH OH NH unsubstituted 23.57±2.7(a) 6.84±2.4(b) 
16 OH H H NH 2-imidazolinyl >100 >100 
17 OH H OH NH 2-imidazolinyl no 6.21±0.4(b) 
18 OH H OCH3 NH 2-imidazolinyl >100 35.69±1.3(b) 
19 OH OH OH NH 2-imidazolinyl 92.92±7.4(b) 32.04±3.7(a) 
BHT OH H 25±4.2(a) 28.0±2.3(a) 
* Values are presented as means ± standard deviation. 
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cynobenzothiazole according to our previously developed 
method.[19] 
 Amidino and 2-imidazolinyl substituted benzi-
midazole derivatives 12–19 were obtained according to 
the experimental procedure shown in the Scheme 2. 
Starting from previously prepared 4-amidino/4-(2-
imidazolinyl)-1,2-phenylenediamines hydrochlorides 11a 
and 11b,[20] due to the cyclocondensation with 
corresponding benzaldehydes 1a–1d in absolute ethanol 
and by using with p-benzoquinone as oxidizing reagent, 
2-phenylbenzimidazole derivatives bearing amidino 
substituents 12–19 were prepared as hydrochloride 
salts. 
 The structures of all newly prepared benzothiazole 
and benzimidazole derivatives were determined by using 
1H and 13C NMR spectroscopy and mass spectrometry. NMR 
analysis based on the values of H-H coupling constants and 
chemical shifts in the 1H and 13C NMR spectra confirmed the 
structures of compounds. Furthermore, IR spectroscopy 
was used for the monitoring of Pinner reaction due to the 
synthesis of main precursors 2a, 2b, 11a and 11b. 
Antioxidative Activity 
In this research we have synthesized benzimidazole and 
benzothiazole derivatives which we envisioned to show 
protection against free radicals attack as an index of 
pharmacological usefulness. To determine antioxidant 
activity of different benzazoles, the reducing activity of the 
stable radical 1,1-diphenyl-picrylhydrazyl (DPPH), free 
radical scavenging ability by the use of radical cation 2,2-
azinobis-(3-ethylbenzthiazoline-6-sulphonic acid (ABTS) 
and ferric reducing/antioxidant power (FRAP) were 
evaluated. The evaluation was conducted by in vitro 
methods which require a spectrometric approach.[25] 
 The radical scavenging assay using stable radical 
DPPH indicates the ability of tested compounds to donate 
proton/electron. The DPPH final concentration was 100 µM 
and results were read after 30 min and presented in Table 
1. The results were expressed as IC50 values with the 
exception of 5, 7, 9, 12 and 17 which did not exhibit activity 
under assay condition. Based on experimental results 
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thiazole derivatives 6 and 10 and benzimidazole derivatives 
15 and 19 exerted scavenging activity towards DPPH. 
 The most potent compounds 6 and 15 have exerted 
IC50 (23.9±4.7 µM; 23.6±2.7 µM, respectively) similar to 
control compound 2,6-bis(1,1-dimethylethyl)-4-methyl-
phenol (BHT) (25.0±4.2 µM) (P > 0.05). The compound 10 
exhibited good antioxidant capacity (34.8±7.0 µM) while 
compound 19 showed lower but still good radical 
scavenging activity (92.9±7.4 µM). The compounds 3, 4, 8, 
13, 14, 16 and 18 showed low antioxidant activity, values 
ranged from 5 to 1 mM. Regarding substitution pattern it 
was evident that with increasing the number of hydroxy 
groups attached on phenyl ring, the scavenging activity was 
improved. 
 Moreover, it was noticed that the type of the 
amidino group attached on the heteroaromatic scaffold 
also influenced the antioxidative activity. Thus, derivatives 
bearing the unsubstituted amidino group 6 and 15 showed 
higher activity in comparison to the derivatives with 2-
imidazolinyl group 10 and 19. In addition, there were no 
any differences in the antioxidative activity between 
benzothiazole or benzimidazole derivatives substituted 
with amidino group 6 and 15. Furthermore, 2-imidazolinyl 
substituted benzothiazole derivative 10 compared to the 
same benzimidazole analogue 19 showed significantly 
higher antioxidative activity but lower than control BHT. 
 Following assay employed in the testing of 
antioxidant ability of benzazole derivatives was ABTS 
radical cation assay at pH 4 as well.[26] The ability of pure 
compounds to decrease the color reacting directly with 
ABTS•+ radical is a measure of their antioxidant capacity. In 
addition, ABTS•+ radicals are more stable then DPPH 
radicals and could be used to evaluate hydrophilic and 
lipophilic compounds.[23] The results are presented as IC50 
in Table 1.  
 Obtained results revealed a higher number of active 
compounds in comparison to the DPPH assay. The different 
number of hydroxy groups attached on the phenyl ring 
strongly influenced the antioxidative activity with the 
trihydroxy substituted derivatives being the most active 
ones. Trihydroxy substituted benzothiazole 6 and 10 and 
benzimidazole 15 and 19 derivatives showed similar activity 
pattern as in the DPPH assay with the 2-imidazolinyl 
substituted benzimidazole 19 showing the weakest activity. 
Moreover, derivatives bearing two hydroxyl groups 4, 8, 13 
and 17 also showed good antioxidative activity. Thus, 
benzimidazole derivatives 13 and 17 exerted improved 
activity in comparison to the same benzothiazole analogues 
4 and 8 with the compounds bearing 2-imidazolinyl group 
being more active. Due to the replacement of one hydroxy 
group with the methoxy group attached on the phenyl ring, 
antioxidative activity was decreased with the benzimi-
dazole derivatives 14 and 18 showing more pronounced 
activity. The most active compounds 4, 6, 8, 10, 13, 15 and 
17 which exhibited antioxidant activity higher then BHT 
ranging from 6.2 to 13.3 µM (P < 0.05). The compounds 18 
and 19 showed almost similar results as control compound 
BHT (35.7±1.3 µM, 32.0±3.7 µM; respectively). 
 The reducing power of investigated compounds was 
determined by FRAP assay. This method is based on the 
ability of compounds to reduce ferric tripyridyl triazine 
complex (TPTZ) to ferrous (Fe2+) form producing an intense 
blue colour as result. 
 The reaction progress is monitored by change in the 
absorbance at 593 nm. Higher increase in the absorbance 
signifies higher reduction potential of investigated 
compounds. The FRAP assay results of tested compounds 
are presented in Figure 2. 
 Presented results revealed that only four derivatives 
6, 10, 15 and 19 showed meaningful ferric reducing 
antioxidative activity. Structure-activity relationship 
revealed also the presence of similar activity pattern as in 
the DPPH assay. The presence of three hydroxy 
substituents on the phenyl ring might play the crucial role 
for ferric reducing antioxidant. 
 All compound showed significantly different FRAP 
values then BHT (P < 0.05). From obtained results the four 
compounds 6, 10, 15 and 19 showed higher reducing ability 
then reference compound BHT (7032.8±310.8, 6884.7± 
109.5, 5719.9±202.7 and 4969.0±336.4 mmol Fe2+/mmolc; 




Within this manuscript, we present the design and 
synthesis of amidino substituted benzothiazole and 
benzimidazole derivatives directly attached to the phenyl 
 
Figure 2. Reducing power of tested compounds measured 
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ring with the variable number of hydroxy and methoxy 
groups. The prepared compounds were synthesized to 
explore their antioxidative activity in vitro. 
 Furthermore, our attention was to study SAR and the 
influence of the number of methoxy and hydroxy groups, 
the type of the heteroaromatic nuclei attached to the 
phenyl ring as well as the type of the amidino group placed 
either on the benzothiazole or benzimidazole moiety on the 
antioxidative activity. 
 The results obtained from the used antioxidative 
assays indicated that the variable number of hydroxy 
groups strongly influenced the antioxidative activity and 
reducing power of tested compounds, among which 
compounds 6, 10, 15 and 19 showed the most pronounced 
activity. Concerning the type of the amidino substituent 
placed at the heteroaromatic scaffold, it could be noticed, 
that in general unsubstituted amidino group had a greater 
impact on the increase of antioxidative activity. Further-
more, there was no significant difference in the anti-
oxidative activity among benzothiazole and benzimidazole 
derivatives. All obtained results pointed out that the new 
series of synthesized derivatives demonstrated a high 
potential for expansion and optimization of their anti-
oxidative activity. 
 
Acknowledgment. This work has been supported by Croatian 
Science Foundation under the projects HRZZ-IP-2013-11-
5596 (Synthesis and cytostatic evaluations of novel nitrogen 
heterocycles library) and under the project (HRZZ-IP-2014-
09-8992) awarded to Tomislav Mašek. The authors have 
declared no conflict of interest. 
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DPPH – 1,1-diphenyl-picrylhydrazyl radical 
ABTS – 2,2'-azinobis(3-ethylbenzthiazoline-6-sulphonic acid) 
FRAP – ferric reducing/antioxidant power 
ROS – reactive oxygen species 
TBHQ – tert-butylhydroquinone 
TMS – tetramethylsilane 
DMSO – dimethylsulfoxide 
TPTZ – tripyridyl-triazine 
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